Search Results - "Shamiyeh, Elias"

Successful within-patient dose escalation of olipudase alfa in acid sphingomyelinase deficiency by Wasserstein, Melissa P., Jones, Simon A., Soran, Handrean, Diaz, George A., Lippa, Natalie, Thurberg, Beth L., Culm-Merdek, Kerry, Shamiyeh, Elias, Inguilizian, Haig, Cox, Gerald F., Puga, Ana Cristina

“…Olipudase alfa, a recombinant human acid sphingomyelinase (rhASM), is an investigational enzyme replacement therapy (ERT) for patients with ASM deficiency…”
Get full text

Cortical Bone Thickness and Bone Mineral Density by Shamiyeh, Souhail G, Shamiyeh, Elias G, Chhaya, Vaishali

Get full text

A randomized, placebo-controlled study of the pharmacokinetics, pharmacodynamics, and tolerability of the oral JAK2 inhibitor fedratinib (SAR302503) in healthy volunteers by Zhang, Meng, Xu, Christine R., Shamiyeh, Elias, Liu, Feng, Yin, Jian Y., von Moltke, Lisa L., Smith, William B.

“…Fedratinib (SAR302503/TG101348) is a Janus kinase 2 (JAK2)‐selective inhibitor in clinical development for the treatment of myelofibrosis. In this randomized,…”
Get full text

Effect of food on the bioavailability and tolerability of the JAK2-selective inhibitor fedratinib (SAR302503): Results from two phase I studies in healthy volunteers by Zhang, Meng, Xu, Christine, Ma, Lei, Shamiyeh, Elias, Yin, Jianyun, von Moltke, Lisa L., Smith, William B.

“…Fedratinib (SAR302503/TG101348) is a Janus kinase 2 (JAK2)‐selective inhibitor developed for treatment of patients with myelofibrosis. The effect of food…”
Get full text

Abstract 563: A prospective biomarker study to demonstrate high MET expression and gene amplification in a subset of patients with advanced gastric cancer by Han-Kwang, Yang, Takeuchi, Hiroya, Kong, Seong-Ho, Lee, Hyuk-Joon, Shamiyeh, Elias, Daskalakis, Nikki, Goulaouic, Hélène, Castell, Christelle, Ozoux, Marie-Laure, Lim, Ju O., Wu, Kaida

“…Abstract Aim: To characterize molecular features of HGF-MET axis in patients (pts) with advanced gastric cancer (GC). Methods: Pts with advanced GC undergoing…”
Get full text

Abstract 3364: A randomized, placebo-controlled study of the tolerability, pharmacokinetics, and pharmacodynamics of the oral JAK2 inhibitor SAR302503 in healthy volunteers by Zhang, Meng, Xu, Christine R., Shamiyeh, Elias, Liu, Feng, Yin, Jianyun, von Moltke, Lisa L., Smith, William B.

“…Abstract Background: SAR302503 is a JAK2 inhibitor in clinical development as a treatment for myelofibrosis (MF). In a phase 1/2 study, SAR302503 provided…”
Get full text

An open-label, multicenter, ascending-repeat-dose study of the tolerability and safety of recombinant human acid sphingomyelinase (rhASM) in patients with ASM deficiency (ASMD) by Wasserstein, Melissa P., Jones, Simon A., Soran, Handrean, Diaz, George, Lippa, Natalie, Thurberg, Beth L., Culm-Merdek, Kerry, Shamiyeh, Elias, Inguilizian, Haig, Puga, Ana Cristina

Get full text